最新的 期临床试验显示 ,由 Aventis/Pfizer公司联合开发的胰岛素干粉吸入制剂 Exubera在控制2型糖尿病病人血糖方面要优于其口服制剂。这项为期 3个月、涉及 3 0 9名 2型糖尿病病人的 期临床研究旨在考察 ,与口服制剂相比 ,Exubera单用或与口服降糖药联用是否能更有效地控制 The latest phase of clinical trials shows that Exubera, an insulin dry powder inhalation co-developed by Aventis / Pfizer, is superior to its oral counterpart in controlling blood glucose in patients with type 2 diabetes. The 3-month, phase 3 clinical trial involving 309 patients with type 2 diabetes mellitus aims to examine whether Exubera alone or in combination with oral hypoglycemic agents can be more effectively controlled than oral formulations